{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:19:55Z","timestamp":1775679595949,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.leukres.2012.06.007","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T19:46:02Z","timestamp":1340999162000},"page":"1296-1299","source":"Crossref","is-referenced-by-count":4,"title":["Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase"],"prefix":"10.1016","volume":"36","author":[{"given":"Felix","family":"Haidl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"October (1)","key":"10.1016\/j.leukres.2012.06.007_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"issue":"September (3)","key":"10.1016\/j.leukres.2012.06.007_bib0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"issue":"December (5)","key":"10.1016\/j.leukres.2012.06.007_bib0015","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"issue":"August (2)","key":"10.1016\/j.leukres.2012.06.007_bib0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1532\/IJH97.07030","article-title":"Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma","volume":"86","author":"Ozaki","year":"2007","journal-title":"Int J Hematol"},{"issue":"July (7)","key":"10.1016\/j.leukres.2012.06.007_bib0025","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdq259","article-title":"Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid","volume":"21","author":"Terpos","year":"2010","journal-title":"Ann Oncol"},{"issue":"February (2)","key":"10.1016\/j.leukres.2012.06.007_bib0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3324\/haematol.2010.031302","article-title":"A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients","volume":"96","author":"Zangari","year":"2011","journal-title":"Haematologica"},{"issue":"October (4)","key":"10.1016\/j.leukres.2012.06.007_bib0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2010.01485.x","article-title":"First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro","volume":"85","author":"Lund","year":"2010","journal-title":"Eur J Haematol"},{"issue":"May (5)","key":"10.1016\/j.leukres.2012.06.007_bib0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan\u2013prednisone vs. melphalan\u2013prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"Delforge","year":"2011","journal-title":"Eur J Haematol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612002743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612002743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T12:23:16Z","timestamp":1542889396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612002743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0145212612002743"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.06.007","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}